OVID News and Press, Ovid Therapeutics Inc. From 05/12/20

NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., MBA, President and Chief Medical O...

Ovid Therapeutics ( OVID ) announced that it had achieved positive results from a Phase 2 study using its drug OV101 to treat patients with Fragile X Syndrome. With this news in hand, that sets up an opportunity for the biotech to meet with the FDA in the coming months in a meeting. This...

RedHill’s COVID 19 Study Receives the FDA Go Ahead RedHill Biopharma Ltd. ( RDHL ) announced that the FDA has approved its plan for starting a mid-stage study for testing out COVID 19 drug candidate. The company’s Investigational New Drug ( IND ) application for a Phase 2a...

ION Geophysical (NYSE: IO ) +87%  on Q1 results . More news on: ION Geophysical Corporation, Tetraphase Pharmaceuticals, Inc., Fastly, Inc., Stocks on the move, , Read more ...

Ovid Therapeutics (NASDAQ: OVID ) announces positive topline results from the signal-finding Phase 2 ROCKET trial of OV101 (gaboxadol), a novel delta (δ)-selective GABA A receptor agonist, in males with Fragile X syndrome. More news on: Ovid Therapeutics Inc., Healthcare stocks n...

Ovid Therapeutics (NASDAQ: OVID ): Q1 GAAP EPS of -$0.37 misses by $0.03 . More news on: Ovid Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Announced earlier today positive topline results from the Phase 2 ROCKET trial of OV101 for the treatment of Fragile X syndrome Previously reported encouraging initial results from Phase 2 ARCADE study in CDKL5 deficiency disorder and Dup15q syndrome Two late-stage clinical readouts expe...

OV101 met the study’s primary objective of safety and tolerability OV101 produced statistically significant reductions in behavioral and functional symptoms in individuals with Fragile X syndrome Results support the continued development of OV101 in Fragile X syndrome NEW YORK...

Ovid Therapeutics ( OVID -9.7% ) announces preliminary data from an ongoing open-label Phase 2 clinical trial, ARCADE , evaluating soticlestat in patients with CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q), two rare developmental and epileptic encephalopathies that are hi...

Soticlestat continues to appear to be safe and well-tolerated; the majority of the 11 patients showed a reduction in seizures All patients that have completed the Phase 2 ARCADE study to date have opted to enroll in the ENDYMION open-label extension study NEW YORK, March 30, 2020 (...